For Relay Therapeutics Inc. (RLAY), 2026 is shaping up to be a make-or-break year, with multiple upcoming clinical milestones for its lead investigational candidate, Zovegalisib.
Zovegalisib is a pan-mutant selective PI3Ka inhibitor. The enzyme, PI3Ka, or phosphoinositide 3-kinase alpha, is involved in numerous cellular functions such as growth, proliferation, and survival, and is the most frequently mutated kinase in all cancers.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.